GlassScriptPhysician profile
David A Hollis
NPI 1467443424
$14,216.88
in general payments reported to CMS, 2019-2025
46 companies · $1,819 in 2025
The $1,819 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,359 · 2020: $1,919 · 2021: $2,103 · 2022: $2,271 · 2023: $1,877 · 2024: $1,869 · 2025: $1,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.58 |
| Education | $132.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,570.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,501.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,001.06 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $950.53 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $929.32 | 2019-2025 | |
| Pfizer INC. | $820.65 | 2019-2025 | |
| Amgen INC. | $725.65 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $597.86 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.59 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $446.76 | 2021-2025 | |
| Lundbeck LLC | $383.24 | 2021-2025 | Vyepti, Rexulti |
| Amarin Pharma, INC. | $367.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $349.27 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $329.97 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $291.81 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hollis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.